Controlled release by Ca(2+)-sensitive recombinant human tumor necrosis factor-alpha liposomes

Area of Science:

• Biotechnology
• Drug Delivery Systems
• Biochemistry

Background:

• Liposomes are versatile nanocarriers for drug delivery.
• Tumor necrosis factor-alpha (TNF-α) is a key inflammatory cytokine with therapeutic potential.
• Controlling the release kinetics of encapsulated biologics is crucial for effective therapy.

Purpose of the Study:

• To develop stable liposomes for encapsulating recombinant human tumor necrosis factor-alpha (rHuTNF).
• To investigate the release characteristics of rHuTNF from liposomes in different physiological environments.
• To explore the influence of liposome composition on rHuTNF release.

Main Methods:

• Entrapment of rHuTNF in liposomes composed of Egg phosphatidylcholine (EggPC) with or without Egg phosphatidic acid (EggPA) or Egg phosphatidylglycerol (EggPG).
• Assessment of liposome stability at 4°C for one month.
• Evaluation of rHuTNF release in rat plasma and phosphate-buffered saline (PBS).
• Investigation of the effect of EDTA and CaCl2 on rHuTNF release.

Main Results:

• Liposomes containing EggPC alone or with EggPG showed stability for one month at 4°C.
• Liposomes incorporating EggPA exhibited controlled release of rHuTNF in rat plasma.
• The release mechanism was identified as calcium ion (Ca2+) dependent, being inhibited by EDTA and induced by CaCl2.
• Increased EggPA content correlated with enhanced rHuTNF release.

Conclusions:

• Stable liposomal formulations of rHuTNF were successfully prepared.
• Liposomes containing EggPA provide a platform for calcium-ion-triggered, controlled release of rHuTNF in plasma.
• This system offers potential for tunable delivery of rHuTNF for therapeutic applications.